Towards Optimal Treatment for High Risk Prostate Cancer

NCT ID: NCT06204341

Last Updated: 2024-09-19

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 207 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-02
• Study Completion Date: 2032-12-18

Brief Summary

The goal of this clinical trial is to combine several optimized treatments of high risk prostate cancer. The main question to answer is: is it safe to combine these optimized treatments.

• patients will be irradiated on the prostate and (elective) lymph nodes more concentrated but with fewer hospital visits (hypofractionation)
• the tumor will get a higher dose
• androgen deprivation therapy will be reduced as much al possible preventing side effects

Researchers will compare oncological outcome and toxicity.

Detailed Description

Rationale: Recently several randomized trial have shown benefits of changes made to radiotherapy of (high risk) localized prostate cancer patients: A focal boost was shown to improve outcome in men with intermediate/high risk prostate cancer (FLAME trial). Elective lymph node irradiation was shown to improve outcome in high risk prostate cancer patients (POP-RT). (Extreme) hypo fractionation was shown to be safe for low/intermediate risk prostate cancer patients. In addition: the added benefit of ADT (with substantial toxicity) seems reduced with improvements made to treatment and diagnosis in recent years (DART 01/05); own recent work on this topic; to be published)). None off the above were combined into one ideal treatment for high risk prostate cancer.

Objective: Determine the safety (oncological outcome and toxicity) of an comprehensive treatment combining recent advances in the treatment of high risk prostate cancer.

Study design: prospective cohort study with matched contemporary control group Study population: Men with high risk prostate cancer with an indication for elective lymph node irradiation Intervention: hypo fractionated pelvic radiotherapy with boost to primary tumour in the prostate Main study parameters/endpoints: biochemical recurrence free survival and late toxicity Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The additional burden of the study is considered to be low, as additional tests or site visits in comparison to current clinical follow up are not planned. Regarding safety, different parts of the investigational treatment were already shown to be safe in previous studies. The current study aims to combine these different parts into one treatment. We estimate that the risks associated with combining these treatments are very limited.

Conditions

High Risk Prostate Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

HYPOPRIME treatment

Hypo fractionated pelvic radiotherapy with boost to primary tumour in the prostate with elective lymph node irradiation and minimized androgen deprivation therapy

Group Type: EXPERIMENTAL

HYPOPRIME treatment

Intervention Type: RADIATION

Hypo fractionated pelvic radiotherapy with boost to primary tumour in the prostate with elective lymph node irradiation and minimized androgen deprivation therapy

Interventions

HYPOPRIME treatment

Hypo fractionated pelvic radiotherapy with boost to primary tumour in the prostate with elective lymph node irradiation and minimized androgen deprivation therapy

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

• Men (aged ≥18 years of age) diagnosed within 6 months before inclusion with high risk prostate cancer:

• T3 based on digital rectal examination AND/OR
• Grade >= 4 AND/OR
• PSA >=20 ug/L
• Indication for elective lymph node irradiation (based on current clinical guidelines) OR N1 on imaging (with a maximum of 4 suspect lymph nodes)

Exclusion Criteria

• Prior pelvic radiotherapy
• TransUrethral Resection of the Prostate (TURP) < 3 months ago
• Prostatectomy or other primary treatment for prostate cancer (e.g. HIFU, cryotherapy, etc)
• contraindications to MRI
• no visible lesion on MRI in prostate for boost
• no PSMA-PET scan
• inflammatory bowel disease
• metastatic disease (M1)
• PSA >50
• unsuitable for SBRT or WPRT
• medical history of cancer other than basal cell carcinoma of the skin

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Tata Memorial Centre

OTHER

Sponsor Role: collaborator

Haaglanden Medical Centre

OTHER

Sponsor Role: lead

Responsible Party

Leonard Bokhorst

MD, PhD, radiation oncologist

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Leonard P Bokhorst, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Haaglanden Medical Centre

Locations

Haaglanden Medical Centre

Leidschendam, South Holland, Netherlands

Site Status: RECRUITING

Countries

Netherlands

Central Contacts

Ursula J Fisscher, PhD

Role: CONTACT

u.fisscher@haaglandenmc.nl

0031889792357

Mirjam E Mast, PhD

Role: CONTACT

m.mast@haaglandenmc.nl

+31 88 9792357

Facility Contacts

Carmen P Liskamp, MD

Role: primary

c.liskamp@haaglandenmc.nl

+31 88 9792357

Mirjam E Mast, PhD

Role: backup

m.mast@haaglandenmc.nl

0031889792357

Leonard P Bokhorst, MD, PhD

Role: backup

Carmen P Liskamp, MD

Role: backup

Other Identifiers

P23.081

Identifier Type: -

Identifier Source: org_study_id